Analyst ratings and price targets can significantly influence a stock's performance. In this case, Keybanc's Overweight rating suggests that they expect Standard BioTools to outperform the market, which could attract investors and drive up the stock price. The price target of $4 also indicates that they believe the stock is undervalued, further suggesting potential for growth.